|
[1]
|
Lamberts SWJ, Hofland LJ, Hofland LJ. Somatostatin anologs in the diagnosis and treatment of cancer[J]. Trends Endocrinol Metab, 2002, 13(3):451-457. |
|
[2]
|
朱小华,吴华.生长抑素受体显像与放射性核素治疗[J].放射学实践,2002,17(6):546-548.
|
|
[3]
|
Van Den, Bossche B, D'haenlnck E, De Vos F, et al. Oestrogenmediated regulation of somatostatin receptor expression in human breast cancer cell lines assessed with 99mTc-depreotide[J]. Eur J Med Mol Imaging, 2004, 31(7):1022-1030. |
|
[4]
|
Shih WJ, Samayoa L. 99mTc-depreotide detecting malignant pulmonary nodules:histopathologic correlation with semiquantitative tumor-to-normal lung ratio[J]. Clin Nucl Med, 2004, 29(3):171-176. |
|
[5]
|
Gsbriel M, Decristoforo C, Donnemiller E, et al. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-oetreotide for diagnosis of somatostatin receptor-expressing tumors[J]. J Nucl Med, 2003, 44(5):708-716. |
|
[6]
|
Pearson DA, Lister-James J, McBride WJ, et al. Somatostatin receptorbinding peptides labeled with technetium-99m:chemistry and initial biological studies[J].J Med Chem, 1996, 39(7):1361-1371. |
|
[7]
|
孙逊,安锐,李烁,等.生长抑素受体显像剂99mTc-HYNIC-TOCA和99mTc-P829在肿瘤模型中的对比研究[J].中国临床医学影像杂志,2006,17(8):438-443.
|
|
[8]
|
Shih WJ, Hirschowitz E, Bensadoun E, et al. Biodistribution on Tc99m labeled somatostatin receptor-binding peptide (depreotide, NeoTec)planar and SPECT studies[J]. Ann Nucl Med, 2002, 16(3):213-219. |
|
[9]
|
Cholewinski W, Kowalczyk JR, Stefaniak B, et al. Diagnosis and staging of children's lymphoma using the technetium-labelled somatostatin analogue, 99mTc-depreotide[J]. Eur J Nucl Med Mol Imaging, 2004, 31(6):820-824. |
|
[10]
|
Shorr AF, Helman DL, Lettieri C J, et al. Depreotide scanning in sarcoidosis:A pilot study[J]. Chest, 2004, 126(4):1337-1343. |
|
[11]
|
Mena E, Camacho V, Estorch M, et al.99mTc-depreotide scintigraphy of bone lesions in patients with lung cancer[J]. Eur Nucl Med Mol Imaging, 2004, 31(10):1399-1404. |
|
[12]
|
Shih WJ, Romero RA, Timothy M, et al. 99mTc-Depreotide chest SPECT demonstrates pulmonary metastases from renal cell carcinoma[J]. J Nucl Med Technol, 2004, 32(1):19-21. |
|
[13]
|
Van Den Bossche B, D'haeninck E, Bacher K, et al. Biodistribution and dosimetry of 99mTc-depreotide(P829)in patients suffering from breast carcinoma[J]. Cancer Biother Radiopharm, 2004, 19(6):776-783. |
|
[14]
|
王峰,王自正,姚薇萱,等.99mTc-生长抑素受体显像对肺癌的诊断价值[J].中华结核和呼吸杂志,2005,28(4):218-220.
|
|
[15]
|
Oberg K, Eriksson B. Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours[J]. Best Pratt Res Clin Endocrinol Metab, 2005, 19(2):265-276. |
|
[16]
|
Blum JE, Handmaker H, Rinne NA. The utility of a somatostatintype receptor binding peptide radiopharmaceutical (P829)in the evaluation of solitary pulmonary nodules[J]. Chest, 1999, 115(1):224-232. |
|
[17]
|
Blum J, Handmaker H, Lister-James J, et al. A multieenter trial with a somatostatin analog 99mTc depreotide in the evaluation of solitary pulmonary nodules[J]. Chest, 2000, 117(5):1232-1238. |
|
[18]
|
Kahn D, Menda Y, Kemstine K, et al.The utility of 99mTc-depreotide compared with 18F-fluorodeoxyglucose positron emission tomography and surgical staging in patients with suspected nonsmall cell lung cromer[J]. Chest, 2004, 125(2):497-501. |
|
[19]
|
王秀娟,李险峰.生长抑素受体肿瘤显像的临床应用及研究进展[J].国际放射医学核医学杂志,2006,30(4):217-219.
|
|
[20]
|
Valsamaki P, Gotzamani-Psarrakou A, Tsiouris S, et al. 99mTc-depreotide imaging of 131I-negative recurrent metastatic papillary thyroid carcinoma[J].Int J Cancer, 2006, 119(4):968-970. |
|
[21]
|
Hellwig D, Samnik M, Reif J, et al. Comparison of 99mTc-depreotide and Indium-111 octreotide in recurrent meningioma[J]. Clin Nucl Med, 2002, 27(11):781-784. |
点击查看大图
下载: